TOM FORD Announces Appointment of Haider Ackermann as Creative Director
4.9.2024 16:30:00 EEST | Business Wire | Press release
TOM FORD announces the appointment of Haider Ackermann as Creative Director, effective immediately.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904332237/en/
Haider Ackermann appointed Creative Director, TOM FORD. (Photo Credit: Ethan James Green)
In his new role, Ackermann will assume the creative leadership across all TOM FORD fashion categories, including menswear, womenswear, accessories, and eyewear, and guide the creative vision for the overall brand. TOM FORD is owned by The Estée Lauder Companies Inc. (NYSE:EL) with the fashion business licensed to the Ermenegildo Zegna Group (NYSE:ZGN) and the eyewear business licensed to Marcolin SpA.
Founder Tom Ford said, “I have long been a great fan of Haider’s work. I find both his womenswear and menswear equally compelling. He is an incredible colorist, his tailoring is sharp, and above all he is modern. We share many of the same historical references, and I could not be more excited to see what he does with the brand. I suspect that I will be the first on my feet to applaud after his show in March.”
A French national born in Bogotá, Colombia, Ackermann's upbringing spanned Ethiopia, Chad, Algeria, The Netherlands, and Belgium, where he studied fashion at the Royal Academy of Fine Arts in Antwerp. Known for blending luxurious fabrics with impeccable tailoring, Ackermann has garnered acclaim for his avant-garde, yet wearable designs favored by celebrities.
“It is with tremendous pride that I will seek to honor the legacy of Tom Ford, a man I have long admired and have the utmost respect for,” said Ackermann. “I am much looking forward to what lies ahead.”
Ackermann's first collection will debut at Paris Fashion Week in March 2025. He will be based in Paris, reporting to Guillaume Jesel, President and CEO, TOM FORD and Luxury Business Development, The Estée Lauder Companies, and to Lelio Gavazza, CEO, TOM FORD FASHION, Ermenegildo Zegna Group.
“Haider stands out as one of the world's most visionary and inspiring talents in fashion. He draws on his deep affinity for global culture and the arts to create arresting fashion and memorable emotional connections. He is the ideal steward to usher TOM FORD into the future," said Jesel.
“I am extremely pleased to welcome Haider as Creative Director of TOM FORD. His unparalleled creativity, which is aligned with the brand's DNA, as well as his renowned experience in luxury will be instrumental in driving the fashion business forward during its next important phase of expansion. Working alongside the talented team at TOM FORD FASHION, Haider’s modern vision, for both men’s and women’s wear, will be essential as we advance and execute the many projects we have in development,” said Gavazza.
About TOM FORD
TOM FORD is a global design house offering exceptional luxury products across women’s and men’s fashion, accessories, eyewear and beauty. Founded in 2005 by Tom Ford, the brand has a presence in more than 100 markets globally and is widely recognized as the architect of luxury glamour. In 2023, The Estée Lauder Companies became the sole owner of the TOM FORD brand and all its intellectual property. In connection with the acquisition, The Estée Lauder Companies established long term licenses with Ermenegildo Zegna Group for TOM FORD FASHION and Marcolin for TOM FORD EYEWEAR.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904332237/en/
Contacts
Press Contact:
Giuseppe Torrisi
TOM FORD, Global Communications Director
Giuseppe.Torrisi@tomfordfashion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom